Commission launches consultation on pharmaceuticals

The European Commission has launched a consultation on the future of pharmaceuticals for human use in Europe, as a part of its programme to improve the regulatory, non-regulatory and research, technology and development framework for pharmaceuticals.

In an explanatory note, the Commission highlights three major challenges impacting the pharmaceutical sector in Europe: the globalisation of the sector; the smooth functioning of the internal market; and advances in science and technology.

On globalisation, the Commission notes that "due to structural factors which go beyond the pharmaceutical sector (e.g. labour costs), the centre of gravity for worldwide R&D investment in the field is gradually moving to the United States and Asia."

Regarding the internal market, the Commission notes that there are still obstacles to the free movement of medicines. Furthermore, the Commission notes that the safety of medicines is a major internal market issues. "Recent analysis has demonstrated the existence of multiple and sometimes inefficient requirements as regards pharmacovigilance in the EU," the Commission writes. "The challenge is thus to strengthen and rationalise drug safety monitoring, while avoiding unnecessary requirements that would impair patients' access to treatments."

Another trend affecting the pharmaceutical sector is the increasingly proactive role of patients regarding their health, and the Commission notes that patients need better access to quality information.

Finally, the Commission identifies advances in sciences and technology such as regenerative medicine, more personalised treatments and the development of nanomedicines, which are all affecting the way medicines are tested and eventually prescribed.

Key questions asked by the Commission concern other challenges to the industry, such as what measure could be implemented to ensure the safety of medicines supplied to the EU, how to improve Europe's international competitiveness and how the EU regulatory framework can be applied to emerging technologies.

For further information, please download (.pdf):
http://ec.europa.eu/enterprise/pharmaceuticals/
pharmacos/docs/doc2007/2007_07/consultationpaper-2007-07-19.pdf

The closing date for contributions is 12 October 2007.

Copyright ©European Communities, 2007
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Philips Foundation 2024 Annual Report: E…

Marking its tenth anniversary, Philips Foundation released its 2024 Annual Report, highlighting a year in which the Philips Foundation helped provide access to quality healthcare for 46.5 million people around...

New AI Transforms Radiology with Speed, …

A first-of-its-kind generative AI system, developed in-house at Northwestern Medicine, is revolutionizing radiology - boosting productivity, identifying life-threatening conditions in milliseconds and offering a breakthrough solution to the global radiologist...

Scientists Argue for More FDA Oversight …

An agile, transparent, and ethics-driven oversight system is needed for the U.S. Food and Drug Administration (FDA) to balance innovation with patient safety when it comes to artificial intelligence-driven medical...

New Research Finds Specific Learning Str…

If data used to train artificial intelligence models for medical applications, such as hospitals across the Greater Toronto Area, differs from the real-world data, it could lead to patient harm...

Giving Doctors an AI-Powered Head Start …

Detection of melanoma and a range of other skin diseases will be faster and more accurate with a new artificial intelligence (AI) powered tool that analyses multiple imaging types simultaneously...

AI Agents for Oncology

Clinical decision-making in oncology is challenging and requires the analysis of various data types - from medical imaging and genetic information to patient records and treatment guidelines. To effectively support...

Patients say "Yes..ish" to the…

As artificial intelligence (AI) continues to be integrated in healthcare, a new multinational study involving Aarhus University sheds light on how dental patients really feel about its growing role in...

Brains vs. Bytes: Study Compares Diagnos…

A University of Maine study compared how well artificial intelligence (AI) models and human clinicians handled complex or sensitive medical cases. The study published in the Journal of Health Organization...

'AI Scientist' Suggests Combin…

An 'AI scientist', working in collaboration with human scientists, has found that combinations of cheap and safe drugs - used to treat conditions such as high cholesterol and alcohol dependence...

Start-ups in the Spotlight at MEDICA 202…

17 - 20 November 2025, Düsseldorf, Germany. MEDICA, the leading international trade fair and platform for healthcare innovations, will once again confirm its position as the world's number one hotspot for...